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Abstract
Background: Part of the inherited risk to lung cancer is likely to include common, low risk alleles.
The identification of this class of susceptibility is contingent on association-based analyses. We
established GEnetic Lung CAncer Predisposition Study (GELCAPS) to collect DNA and clinico-
pathological data from a large series of cases and a series of spouse/partner controls, thereby
generating a key resource for the identification of low risk alleles.
Methods: GELCAPS was one of the first genetic epidemiological trials in the UK to be adopted by
the National Cancer Research Network (NCRN) onto its portfolio with the participation of over
100 oncology departments specialising in the management of lung cancer.
Results: Samples from over 5,000 independent lung cancer cases and 2,000 controls have so far
been assembled through GELCAPS.
Conclusion: GELCAPS represents one of the largest datasets of its type in the world capable of
informing on the contribution of low penetrance alleles to the development of lung cancer and the
influence of genetic variation on outcome. In addition our experience in developing the GELCAPS
serves to illustrate how large DNA biobanks for genetic analyses can be rapidly generated within
the UK using the NCRN.
Background
Lung cancer is a major cause of cancer mortality world-
wide [1]. In the United Kingdom, it accounts for more
than 33,000 cancer deaths each year (Cancer Research
UK). The disease is frequently cited as a malignancy solely
attributable to environmental exposure, principally
tobacco smoking. It has, however, long been postulated
that individuals may differ in their susceptibility and there
is strong evidence from epidemiological studies for a
familial risk [reviewed in [2]]. Direct evidence for a genetic
predisposition is provided by the increased risk of lung
cancer associated with a number of rare Mendelian cancer
syndromes, such as in carriers of germline TP53 [3]and RB
[4,5] mutations, as well as in patients with Bloom's [6]
and Werner's [7] syndromes.
The two major types of lung cancer, non-small cell lung
cancer (NSCLC), and small cell lung cancer (SCLC)
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account for 75% and 25% of cases respectively. Although
the histological features are different between these
(reflected in differences in patterns of gene expression),
there are similarities in the spectrum of underlying
somatic genetic alterations suggesting commonality in
pathogenesis. Moreover, the observation that the familial
risks are not subtype dependent [8-13] and that histolog-
ical concordance between affected family members is
poor [9] is consistent with the hypothesis of a "generic"
inherited susceptibility to lung cancer.
The genetic basis of inherited susceptibility to lung cancer
outside the context of the rare Mendelian cancer predispo-
sition syndromes is at present undefined, but a model in
which major gene loci account for the excess familial risk
seems unlikely. One hypothesis about the allelic architec-
ture of susceptibility proposes that part of the genetic risk
is caused by disease loci, which include common, low
penetrance alleles. This "common-disease common-vari-
ant" hypothesis implies that conducting association anal-
yses based on scans of Single Nucleotide Polymorphisms
(SNPs) should be a powerful strategy for identifying low-
penetrance variants [14,15].
Previous studies aimed at identifying low penetrance alle-
les for lung cancer susceptibility have largely been based
on a candidate gene approach formulated on preconcep-
tions as to the role of specific genes in the development of
the disease. Perhaps not surprisingly most studies have to
date only evaluated a restricted number of polymor-
phisms, primarily in genes implicated in the metabolism
of tobacco-associated carcinogens and the protection of
DNA from carcinogen-induced damage. However, with-
out a clear understanding of the biology of lung cancer
predisposition the definition of suitable genes for the dis-
ease is inherently problematic making an unbiased
approach to loci selection highly desirable.
Despite much research, few definitive low penetrance sus-
ceptibility alleles for lung cancer have been to date une-
quivocally been identified through candidate-based
association studies. As with many other diseases, positive
associations have been reported for various polymor-
phisms of genes such as GSTT1 [16], GSTM1 [17], ERCC2
[18], CYP1A1 [19], and TP53 [20] from small studies, but
few of the initial positive results have been replicated in
subsequent studies. The inherent statistical uncertainty of
case-control studies involving just a few hundred cases
and controls seriously limits the power of such studies to
reliably identify genetic variants conferring modest but
potentially important risks.
In addition to genetic variation affecting the risk of devel-
oping cancer it is increasingly being recognised that
genetic variation, not necessarily in the same genes, may
also affect clinical outcome. As with case-control associa-
tion studies aiming to identify novel susceptibility alleles
the same issues of study power pertain to the search for
prognostic markers and such studies are again contingent
on access to large case-series.
Following the sequencing of the human genome, large-
scale harvests of SNPs have been conducted and > 10 mil-
lion documented. Patterns of linkage disequilibrium (LD)
between SNPs have been characterised allowing subsets of
SNPs (tagging SNPs) to be selected that capture a large
proportion of the common sequence variation in the
human genome. This coupled with the advent of highly
efficient analytical platforms allow whole genome-wide
studies (GWAS) for disease associations to be conducted
cost effectively. The relationship between patients' geno-
type and risk of lung cancer is now open for exploration.
The identification of genes associated with cancer predis-
position and determination of their contribution to dis-
ease incidence are contingent on having DNA samples
from large, systematic series of cancer patients. The result-
ing genetic epidemiological data provides the informa-
tion on which to base the identification, counselling and
management of at-risk individuals. The National Cancer
Research Network (NCRN) was established to provide
support for clinical cancer research in England and is one
of the most substantial and constructive developments in
the area of cancer research to be made in recent years in
the United Kingdom. In England, serving a population of
50 million people, the NCRN is made up of 34 geograph-
ically distinct Networks covering the entire country.
Within each Network there are clinical research support
staff and infrastructure to promote accrual of patients into
trials and studies, and the collection of high quality clin-
ico-pathological data and appropriate biological samples.
Hence the NCRN presents a major scientific initiative not
only in the field of clinical trials but also in the field of
genetic epidemiology.
To create a resource for identifying low penetrance alleles
for lung cancer we established GELCAPS (GEnetic Lung
CAncer Predisposition Study) in March 1999 to collect
DNA and clinico-pathological data from a large series of
lung cancer cases. Within 5-years of setting up the initia-
tive by linkage with the NCRN it has been possible to cre-
ate a world-class resource of biological and clinico-
pathological data from over 5,000 individuals with lung
cancer.
Methods/Design
Eligibility criteria
All patients diagnosed with lung cancer between March
1999 and July 2004 were eligible for the study. To ensure
that data and samples were collected from bona fide lungBMC Cancer 2008, 8:244 http://www.biomedcentral.com/1471-2407/8/244
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cancer cases and avoid issues of bias from survivorship
only incident cases with histologically or cytologically
(only if not adenocarcinoma) confirmed primary disease
were ascertained. Partners of recruited lung cancer
patients with no personal history of cancer were recruited
as controls.
Procedural outline
A standardised questionnaire was used to collect basic
demographic characteristics-sex, date of birth, ethnic
group (White, Black-Caribbean, Black-African, Black-
other, Indian, Pakistani, Chinese, Other), country of
birth, current area of residence – in addition to details on
active and past smoking history (including type of
tobacco product, amount smoked, age at first cigarette
and age at any major change of smoking habits), exposure
to asbestos, occupational history, and personal past med-
ical history. All questionnaires were self-administered and
no surrogate responders were used. An open question was
used to obtain information on family history of cancer
involving first-degree relatives. A positive history of lung
cancer was only assigned when detailed information was
provided identifying the family member affected by lung
cancer. The referring clinician using a standard registra-
tion form supplied clinico-pathological details (type of
lung cancer, stage at presentation) of patients.
Coupled with patient recruitment their spouses/partners
who had no known past or current history of malignancy
were invited to participate for the purposes of contribut-
ing to the generation of a control series. For these individ-
uals details of sex, date of birth, ethnic group, place of
birth, current area of residence and smoking history were
collected through a self-administered questionnaire. 10–
20 ml EDTA-venous blood samples were collected from
all participants. Consent forms, questionnaires, registra-
tion forms and blood samples were returned to the Insti-
tute of Cancer Research (ICR) by mail. Blood samples
collected were stored at -80°C prior to DNA extraction
and quantification.
It is our intention to collect outcome data on all cases
entered into GELCAPS. In the first stage of this process
subsets of participating centers were asked to provide the
clinical details on the outcome of the recruited lung can-
cer patients. Records were requested based on their date of
accrual, with those accrued at the beginning of the study
being requested first. A standard proforma was used to
collect information on diagnosis, stage, treatment and
survival. Fully informed consent was obtained from all
patients alive at the time of outcome data collection. Out-
come forms were returned to the ICR by mail and details
were stored electronically.
Statistical considerations
The primary aim of establishing GELCAPS was to generate
a DNA resource of lung cancer patients sufficiently large to
robustly identify low penetrance alleles by association
studies of genetic polymorphisms. From the outset we
envisaged that at some juncture such searches would be
conducted on a genome-wide basis. It is well recognised
that as such studies involve typing a vast number of mark-
ers, a large number of false positive associations will inev-
itably be generated and only a small number of markers
will be truly associated with disease susceptibility. Hence
associations need to attain a high level of statistical signif-
icance to be established beyond reasonable doubt and sig-
nificance levels of ~10-7 have been proposed as being
appropriate [14]. The original target of GELCAPS was to
assemble a series to include ~2,000 cases. This figure had
been arrived upon on the basis of upon contemporaneous
views of the probable impact of common alleles on dis-
ease risk. During development of GELCAPS studies of
other common diseases indicated that common disease
alleles are likely to be associated with risks typically in the
range of 1.1–1.5. To identify alleles conferring such risks
is contingent on sample sets twice that of our original tar-
get and we therefore revised our target accordingly in
order to have ~80% power to identify an association
between SNP genotype and risk.
Ethical considerations
In generating DNA registries such as GELCAPS ethical
considerations are central to study design. One of the par-
ticular strengths of studies such as GELCAPS is that once
constructed the DNA database can be probed repeatedly
for different existing and newly identified candidate risk
factor genes. It is not feasible to contact all study entrants
to seek further written consent for specific test therefore,
the information sheet and study discussion was centred
on the general concept of 'genetic analyses'. As these
investigations were to be solely for research to find new
gene(s) predisposing to cancer it was implicit that no indi-
vidual results will be conveyed to persons. In publications
of findings no study entrant would be identifiable. As
with all studies of this nature we clearly stated that if a
study entrant wished to withdraw their DNA sample and
all information held on them would be destroyed. To
ensure confidentiality data is held under secure condi-
tions at the ICR Institute of Cancer Research and informa-
tion held on study entrants will not be divulged to any
person or agency without the prior written agreement of
the study entrant.
All clinical information and biological samples were
obtained only after fully informed consent was obtained
from participating individuals, and in accordance with the
tenets of the Declaration of Helsinki. Ethical approval for
the study was obtained from the London Multi-CentreBMC Cancer 2008, 8:244 http://www.biomedcentral.com/1471-2407/8/244
Page 4 of 10
(page number not for citation purposes)
Research Ethics Committee (MREC/98/2/67) and local
ethical committees. Personal information was stored in
accordance with the Data Protection Act (1998).
Extraction of DNA, storage and quality assurance
DNA was extracted from EDTA blood samples using either
a standard salt extraction procedure or using the
Chemagen system (Chemagen Biopolymer-Technologie
AG, Arnold-Somerrfield-Ring 2, 5499 Baeswelder, Ger-
many, Picogreen quantified (Quant-it, Invitrogen, Paisely,
UK) and normalised to 100 ug/ul in TE buffer. DNAs
stocks are being stored in Eppendorf tubes
(Barkhausenwe 1 22339 Hamburg, Germany) at -80°C.
To avoid subjecting stock DNAs being to repeated thawing
and freezing we have generated a series of "master" 96
deep well plates of samples from which DNAs can be
readily robotically abstracted for genotyping studies.
Fidelity of DNA is being constantly evaluated by monitor-
ing performance in the different genotyping platforms.
Results
After securing ethical permissions at a national level
through the Multi Research Ethics Committee we started
recruitment to GELCAPS in March 1999. Ascertainment of
cases was restricted to 28 centres and accrual was maxi-
mally 10–20 patients per month. After GELCAPS was
incorporated into the NCRN (National Cancer Research
Network) portfolio in March 2002 it was subsequently
rolled out across England after individual centers had
obtained local ethical permissions. Adoption by the
NCRN was associated with a significant increase in patient
and control accrual (Figure 1). Eventually 140 oncology
centers (Figure 2) became active participants in GELCAPS
with patient ascertainment averaging ~100 cases per
month. The remit and operational procedure by which
patients are accrued to NCRN adopted studies does not
allow collection of compliance data within each partici-
pating center. However, we estimate based on our inti-
mate knowledge of the clinical activities of three centers
that patient accrual to GELCAPS is ~70% of those invited
to participate.
The original target of GELCAPS was to assemble a series of
2,000 lung cancer cases. Given the efficiency by which
samples were being accrued following adoption of GEL-
CAPS by the NCRN a new target of at least 4,000 cases was
deemed to be eminently feasible within the time frame for
which funding had been secured.
We terminated accrual to GELCAPS in July 2004 by which
time samples from 5,269 cases with primary lung cancer
and 2,094 controls had been recruited. The majority of
cases were male (64%) reflecting the sex preponderance of
disease. Whilst the mean age of controls was comparable
to cases (62.9 years, SD = 10.6) not surprisingly 69% were
female (Table 1). Similarly, the prevalence of smoking
was significantly higher amongst cases compared to con-
trols. A high proportion of the cases ascertained had been
diagnosed with lung cancer at a young age (Table 1); spe-
cifically 1,617 (~31%) of the cases were aged less than 60
years old at diagnosis, compared with < 10% in the gen-
eral population. The frequency of the various forms of
lung cancer was, however, in keeping with that observed
in UK general population – ~23% being affected with
SCLC and ~73% with NSCLC (Table 1).
To date we have acquired follow up data on 1,187
patients; specifically, information on the staging, manage-
ment and clinical outcome permitting comparison
patients randomly drawn from the general population.
Stage at presentation for each of the different subtypes of
lung cancer was similar to that observed in the general
population; specifically, for patients with SCLC, some-
what less than half (43%) presented with limited disease
and of the patients with NSCLC, 13% had stage I, 15%
had stage II, 43% had stage III, and 29% had stage IV dis-
ease. The majority of patients with limited stage SCLC had
been treated with a combination of radical radiotherapy
and chemotherapy, whilst all patients received chemo-
therapy. The main treatment modality for SCLC patients
with extensive disease was chemotherapy. Patients with
early stage NSCLC (stage I and II disease) were mainly
treated with surgical resection of the primary tumor whilst
about one third received chemotherapy and radical radio-
therapy. The mainstay treatment modality of patients with
stage III and IV NSCLC was chemotherapy. Overall the
median survival time (MST) for the subset of 1,187 GEL-
CAPS patients was 18.6 months. Prognosis was signifi-
cantly correlated with stage at presentation, with those
Accrual of cases and controls to GELCAPS Figure 1
Accrual of cases and controls to GELCAPS.
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presenting early have a far better survival (Figure 3).
Patients with SCLC had a MST of 26.0 and 10.5 months if
diagnosed with limited and extensive disease respectively.
For those with NSCLC, MSTs ranged from 12.1 months
for stage IV patients to 32.3 months for stage I disease.
Discussion
Recent data from GWASs of breast [21,22], prostate [23-
27] and colorectal (CRC) cancer [28-31] provides strong
evidence for the involvement of common disease-causing
alleles and suggests that a relatively large number of genes
Centres in the UK recruiting to GELCAPS after NCRN adoption Figure 2
Centres in the UK recruiting to GELCAPS after NCRN adoption.
(18)BMC Cancer 2008, 8:244 http://www.biomedcentral.com/1471-2407/8/244
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Table 1: Characteristics of lung cancer patients recruited to GELCAPS
Cases Controls
Total 5,269 2,094
Gender (Male: Female) 3,382 (64.2%) 645 (30.8%)
Age at diagnosis (years) 887 (35.8%) 446 (69.1%)
<40 53 (1.0%) 64 (3.1%)
40–49 302 (5.7%) 166 (7.9%)
50–59 1,146 (21.7%) 514 (24.5%)
60–69 1,868 (35.4%) 756 (36.1%)
70–79 1,590 (30.1%) 510 (24.4%)
80+ 310 (5.9%) 84 (4.0%)
Mean (SD) 65.1 (10.0) 62.9 (10.6)
Ethnicity
Arabic 3 (0.05%) 1 (0.05%)
Asian 7 (0.13%) 6 (0.29%)
Bangladeshi 1 (0.01%) 0
Black-African 4 (0.08%) 1 (0.05%)
Black-Caribbean 31 (0.59%) 8 (0.38%)
Black-Other 1 (0.01%) 0
Indian 16 (0.30%) 4 (0.19%)
Jewish-Ashkenazi 12 (0.22%) 6 (0.29%)
Pakistani 8 (0.15%) 0
White 5,065 (96.1%) 1,947 (93.0%)
Other/not specified 82 (1.6%) 121 (5.8%)
Reported asbestos exposure 807 (15.2%) 125 (6.0%)
Family history of lung cancer 750 (14.2%) 212 (10.1%)
Smoking habits
Never-smokers 307 (5.8%) 718 (34%)
All smokers
Age first started smoking (SD) 16.5 (4.0) 17.9 (4.8%)
Pack years in Smokers (SD) 47.2 (30.6) 30.4 (22.1%)
Histology of cancer
Small cell (SCLC) 1,193 (22.6%)
Non-small cell (NSCLC) 3,815 (72.4%)
Squamous 1,905 (49.9%)
Adenocarcinoma (including variants) 1,110 (29.1%)
Large cell 10 (0.3%)
Brochoalveolar 44 (1.2%)
Adenosquamous 11 (0.3%)
Neuroendocrine 20 (0.5%)
NSCLC unspecified 715 (18.7%)
Sarcoma 5 (0.1%)
Unclassified primary 256 (4.9%)
Tumour stage at presentation, by histology
SCLC
Limited 168 (50.4%)
Extensive 165 (59.6%)
NSCLC
I 151 (14.1%)
II 140 (13.1%)
III 457 (42.7%)
IV 323 (30.2%)BMC Cancer 2008, 8:244 http://www.biomedcentral.com/1471-2407/8/244
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influence the aetiology in most cancers in the patient pop-
ulation as a whole.
To exploit the advances brought about by the human
genome projects, future work in cancer genetics will be
dependent upon the acquisition of large well-character-
ised cohorts of cancer cases. Here we have demonstrated
that the centralisation of cancer services in the UK offers
an opportunity to establish large, well-characterised
cohorts by targeting collection to the largest centres.
Moreover mobilising NCRN networks provides a means
of delivering consistently the data and sample collection
to complete genetic epidemiology studies, relating to the
detection of main effects on the required scale.
Because ascertainment of cases through GELCAPS has
been based on clinical centres specialising in the treat-
ment of lung cancer a high proportion of cases have been
diagnosed young. While this means cases are not fully rep-
resentative of disease in the general population the distri-
bution of age at diagnosis serves to empower GELCAPS
for identifying disease-causing alleles by virtue of genetic
enrichment.
Given that constitutional genotypes may well influence
patient prognosis it is highly desirable that survivorship is
not confounding influence on sample collection. As sur-
vival rates in patients recruited to GELCAPS were not sig-
nificantly different to those documented in previously
published audits of lung cancer in the UK there is no evi-
dence that "healthy study participant" selection will have
genetically biased ascertainment. For all participants, sex,
ethnicity and age at sampling have been documented. The
geographical area of birth and area of residence within the
UK is known for all of the individuals and this informa-
tion can be used to allow analyses stratified by region of
residence, reducing any effects of population stratifica-
tion. The possibility of population stratification leading to
false inference of disease-genotype association can readily
be addressed by adjusting for known region/ethnicity or
by using information on unlinked genetic markers.
We acknowledge the potential problem of differential bias
in genotyping samples accrued from different sources.
Although the samples collected through GELCAPs have
been ascertained from many clinical centres we have no
evidence that this has affected sample quality as we have
previously documented call rates of 99.8% in samples
genotyped for 1,500 SNPs [32-35] and Quantile-Quantile
plots of test association statistics provide no evidence for
differential bias
The NCRN research networks are established within can-
cer care networks where access to partners is readily avail-
able and direct. They are not designed to collect samples
from the general population so our choice of collecting
samples from partners was a pragmatic one appropriate
for the NCRN. Inevitably in studies such as GELCAPS a
smaller number of samples from controls will be collected
than from cases since in addition to lack of compliance
many patients do not have a current partner. The sex of
controls ascertained through initiatives such as GELCAPS
will usually be of the opposite gender to cases, and con-
Survival from lung cancer in patients according to stage at  presentation: A) Patients with SCLC, B) Patients with  NSCLC Figure 3
Survival from lung cancer in patients according to 
stage at presentation: A) Patients with SCLC, B) 
Patients with NSCLC. In both SCLC and NSLC survival 
was significantly better (P < 0.0001) in patients presenting 
with early stage disease compared to those presenting with 
late stage disease in both Log rank tests of the difference in 
distribution of survival curves and in Cox-proportional haz-
ard test, adjusting for age, sex, year of presentation and 
treatment with platinum-based chemotherapy. Statistical 
analyses performed using STATA version 8.0 (College Sta-
tion, Tx, USA).
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trols are potentially over-matched with respect to many
lifestyle risk factors. Theses limitations can be offset to a
large degree by using samples collected from the healthy
spouses/partners of one cancer as a source of controls for
a different cancer. This is something we are currently pur-
suing with respect to a similar NRCN sponsored initiative
the National Study of Colorectal Cancer Genetics
(NSCCG)
Because of the difficulty of obtaining sufficiently detailed
data on environmental exposure in studies such as GEL-
CAPS, and because there are issues to do with comparabil-
ity of exposure data from controls assembled from
different studies, it is acknowledged that studies of envi-
ronmental risk factors including gene-environment inter-
action will be limited in resources such as GELCAPS. The
main value of collections such as GELCAPS will be in
studies of genetic risk factors and gene-gene interactions;
hypotheses regarding gene-environment interaction
require alternative datasets, such as the European Prospec-
tive Investigation into Cancer and nutrition (EPIC) study
[36], which are centred around population based-cohorts.
Accepting such limitations our experience in developing
GELCAPS serves to illustrate how large DNA databases for
genetic analyses can rapidly be developed in the UK. At
present we have only collected outcome data on around
20% of cases recruited to GELCAPS. By completing the
collection of follow up data on all cases we shall be able
to assemble a unique series for examining the influence of
constitutional genotype on clinical outcome in the popu-
lation setting.
Conclusion
Finally, it is noteworthy that the value of GELCAPS has
been demonstrated in a recent GWAS of lung cancer we
have conducted in which we have been able to robustly
identify a susceptibility variant for the disease mapping to
15q [37].
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